20 citations
,
June 2019 in “Archives of dermatological research” Combining DPCP and anthralin helps regrow hair in some alopecia areata patients.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
January 2024 in “Journal of Clinical Images and Medical Case Reports” Baricitinib may help treat frontal fibrosing alopecia and facial papules.
June 2023 in “Oriental Journal of Chemistry/Oriental journal of chemistry” New compounds may help treat prostate cancer by reducing cell growth.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
January 2017 in “Nasza Dermatologia Online” Both treatments helped hair regrowth in alopecia areata, with isopropanol being better tolerated.
20 citations
,
March 2013 in “Journal of Lipid Research” The research explains how a human enzyme binds and processes its substrate, which could relate to its role in biological functions and hair loss.
5 citations
,
September 2011 in “Bioorganic & Medicinal Chemistry Letters” Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
31 citations
,
February 1972 in “Experientia” The diphosphonate was the most effective at preventing calcification in rats.
December 2024 in “Journal of General-Procedural Dermatology & Venereology Indonesia” The serum effectively reduces hair loss and improves hair growth without side effects.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
59 citations
,
January 2015 in “Nanoscale” The new micelle formulation delivers acne treatment more effectively and safely than current gels.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
February 1977 in “Archives of Dermatology” Topical mitotic blocking agents like colchicine can be dangerous and potentially fatal, and hair loss from rapid weight loss is due to low protein, not the speed of weight loss.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
19 citations
,
January 2019 in “JAAD case reports” A medication for skin rash also unexpectedly treated hair loss in a patient.
June 2024 in “Advances in therapy” IVL3001 is safe, effective, and better than oral finasteride for treating hair loss.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
5 citations
,
December 2021 in “Frontiers in Cell and Developmental Biology” Enzymes called PADIs play a key role in hair growth and loss.
1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
69 citations
,
December 2015 in “Journal of Controlled Release” Nanocapsules can improve clobetasol delivery to hair follicles, reducing side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
20 citations
,
October 2003 in “The Journal of Dermatology” DCP therapy causes side effects like weakness, flushing, headaches, and taste changes, but less frequently causes hypertension and diabetes.